このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Smith & Nephew 将来の成長

Future 基準チェック /46

Smith & Nephew利益と収益がそれぞれ年間21.7%と5%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に16.6% 22.7%なると予測されています。

主要情報

22.7%

収益成長率

25.8%

EPS成長率

Medical Equipment 収益成長	22.9%
収益成長率	5.3%
将来の株主資本利益率	16.5%
アナリストカバレッジ	Good
最終更新日	27 Sep 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

BATS-CHIXE:SNL - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	6,445	765	736	1,248	17
12/31/2025	6,133	641	670	1,120	18
12/31/2024	5,817	462	520	983	18
6/29/2024	5,642	305	301	733	N/A
3/29/2024	5,596	284	241	671	N/A
12/31/2023	5,549	263	181	608	N/A
9/30/2023	5,449	241	102	491	N/A
7/1/2023	5,349	218	22	374	N/A
4/1/2023	5,282	221	66	421	N/A
12/31/2022	5,215	223	110	468	N/A
9/30/2022	5,214	360	213	595	N/A
7/2/2022	5,213	496	315	721	N/A
4/2/2022	5,213	510	392	799	N/A
12/31/2021	5,212	524	469	877	N/A
9/30/2021	5,168	539	632	1,051	N/A
7/3/2021	5,124	553	795	1,225	N/A
4/3/2021	4,842	501	644	1,080	N/A
12/31/2020	4,560	448	492	935	N/A
9/30/2020	4,624	420	420	863	N/A
6/27/2020	4,688	391	347	790	N/A
3/27/2020	4,913	496	554	979	N/A
12/31/2019	5,138	600	760	1,168	N/A
9/30/2019	5,044	649	762	1,127	N/A
6/29/2019	4,949	698	763	1,085	N/A
3/29/2019	4,927	681	674	1,008	N/A
12/31/2018	4,904	663	584	931	N/A
9/30/2018	4,887	690	622	984	N/A
6/30/2018	4,869	717	660	1,036	N/A
3/31/2018	4,817	742	N/A	1,063	N/A
12/31/2017	4,765	767	N/A	1,090	N/A
9/30/2017	4,721	817	N/A	1,011	N/A
7/1/2017	4,677	867	N/A	931	N/A
4/1/2017	4,673	826	N/A	890	N/A
12/31/2016	4,669	784	N/A	849	N/A
9/30/2016	4,680	570	N/A	829	N/A
7/2/2016	4,690	356	N/A	809	N/A
4/2/2016	4,662	383	N/A	920	N/A
12/31/2015	4,634	410	N/A	1,030	N/A
9/30/2015	4,702	513	N/A	1,062	N/A
6/27/2015	4,669	557	N/A	940	N/A
3/27/2015	4,680	499	N/A	837	N/A
12/31/2014	4,617	501	N/A	683	N/A
9/27/2014	4,543	503	N/A	702	N/A
6/28/2014	4,422	523	N/A	753	N/A
3/29/2014	4,349	563	N/A	766	N/A
12/31/2013	4,351	556	N/A	867	N/A
9/28/2013	4,253	534	N/A	798	N/A

アナリストによる今後の成長予測

収入対貯蓄率: SNLの予測収益成長率 (年間21.7% ) は貯蓄率 ( 1.8% ) を上回っています。

収益対市場: SNLの収益 ( 21.7% ) はUK市場 ( 13.1% ) よりも速いペースで成長すると予測されています。

高成長収益: SNLの収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: SNLの収益 ( 5% ) UK市場 ( 3.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: SNLの収益 ( 5% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: SNLの自己資本利益率は、3年後には低くなると予測されています ( 16.6 %)。

Smith & Nephew 将来の成長

Future 基準チェック /46

主要情報

今後の成長に関する最新情報

Smith & Nephew plc Provides Revenue Guidance for the Second Half and Reaffirms Earnings Guidance for the Year 2024

Smith & Nephew plc Provides Earning Guidance for Full Year 2023

Smith & Nephew plc Increases Revenue Guidance for 2023

Smith & Nephew plc Announces Revenue Guidance for 2022

Smith & Nephew plc Provides Revenue Guidance for the Second Half and Full Year of 2022

Smith & Nephew plc Provides Revenue Guidance for the Second Half and Year of 2022

Recent updates

Smith+Nephew Announces Board and Committee Changes

Smith & Nephew plc Provides Revenue Guidance for the Second Half and Reaffirms Earnings Guidance for the Year 2024

Smith+Nephew Announces 510(K) Clearance of New Catalysystem Primary Hip System

Cevian Capital II GP Limited acquired 5.02% stake in Smith & Nephew plc (LSE:SN.).

Smith & Nephew plc Announces Final Dividend of the Year Ended 31 December 2023, Payable on May 22, 2024

Smith & Nephew plc to Report First Half, 2024 Results on Aug 01, 2024

Smith+Nephew Introduces the RENASYS EDGE Negative Pressure Wound Therapy System

Smith & Nephew plc Announces Board Changes

Upcoming dividend of US$0.23 per share

Smith & Nephew plc, Annual General Meeting, May 01, 2024

Final dividend of US$0.23 announced

Smith & Nephew plc Recommends Final Dividend for 2023, Payable on May 22, 2024

Full year 2023 earnings released: EPS: US$0.30 (vs US$0.26 in FY 2022)

Smith+Nephew Announces Commercial Launch of Its Aetos Shoulder System for Anatomic and Reverse Shoulder Replacement At Aaos 2024 Annual Meeting

Smith & Nephew plc Announces Standout Results for Its Regeneten Bioinductive Implant from A Recently Completed Randomized Controlled Trial

Smith & Nephew plc (LSE:SN.) acquired CartiHeal (2009) Ltd.

Smith+Nephew Announces Board Changes

Smith+Nephew Announces Board Changes

Smith & Nephew plc (LSE:SN.) entered into a definitive agreement to acquire CartiHeal (2009) Ltd. for $330 million.

Smith & Nephew plc Provides Earning Guidance for Full Year 2023

Smith & Nephew plc Announces Appointment of John Rogers as CFO

Smith & Nephew plc Announces Interim Dividend for 2023, Payable 1 November 2023

Upcoming dividend of US$0.14 per share at 3.0% yield

Smith & Nephew plc Announces Board and Committee Changes

Smith & Nephew plc Increases Revenue Guidance for 2023

First half 2023 earnings released: EPS: US$0.20 (vs US$0.20 in 1H 2022)

Smith & Nephew plc Announces Step Down of Anne-Françoise Nesmes as Chief Financial Officer

Smith+Nephew Announces 510(K) Clearance of its AETOS Shoulder System

Chief Human Resources Officer recently sold UK£51k worth of stock

Now 22% undervalued

Now 20% undervalued

Insider recently bought UK£117k worth of stock

Upcoming dividend of US$0.23 per share at 2.6% yield

Chief Human Resources Officer recently sold UK£111k worth of stock

Full year 2022 earnings released: EPS: US$0.26 (vs US$0.60 in FY 2021)

Smith & Nephew plc, Annual General Meeting, Apr 26, 2023

Now 21% undervalued

High number of new directors

Smith & Nephew plc to Report Fiscal Year 2022 Results on Feb 21, 2023

Smith & Nephew plc Announces Revenue Guidance for 2022

Smith+Nephew Expands Procedural Innovation with Introduction of JOURNEY(TM) II ROX(TM) Total Knee Solution

Smith+Nephew First to Market with Revision Knee Indication on Robotics Platform

Upcoming dividend of US$0.14 per share

Smith+Nephew Launches OR3O ™ Dual Mobility System in Japan for Use in Primary and Revision Hip Arthroplasty

Smith+Nephew Announces New Data Furthering a Number of Published Studies Supporting the Use of Its REGENETEN Bioinductive Implant in Rotator Cuff Repair

Smith & Nephew plc to Report Q2, 2023 Results on Aug 03, 2023

Smith & Nephew plc Announces Executive Changes

Chairman recently bought UK£59k worth of stock

First half 2022 earnings released

Smith & Nephew plc Provides Revenue Guidance for the Second Half and Full Year of 2022

Smith+Nephew Launches Clinical Support App to Help Reduce Practice Variation in Wound Care

Smith & Nephew plc Announces Executive Changes

Smith & Nephew plc Announces Executive Changes

Smith+Nephew Announces First Total Hip Replacement Cases on its CORI Surgical System Using RI.HIP Modeler and RI.HIP Navigation

High number of new directors

Smith+Nephew Announces New Study Showing GRAFIX™ Membrane Cut the Rate of Diabetic Foot Ulcer Recurrence in Half Compared to Leading Competitors

Upcoming dividend of US$0.23 per share

Independent Non-Executive Director recently bought UK£59k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Smith & Nephew plc, Annual General Meeting, Apr 13, 2022

Smith & Nephew plc Provides Revenue Guidance for the Second Half and Year of 2022

Smith+Nephew Expands Next-Generation Handheld Robotic-Assisted CORI™ Surgical System into Total Hip Arthroplasty with RI.HIP NAVIGATION

Smith+Nephew Announces New Indications for Use for its PICO 7 and PICO 14 Single Use Negative Pressure Wound Therapy Systems

Smith & Nephew plc (LSE:SN.) acquired Engage Surgical.

Now 24% undervalued

Smith & Nephew plc (LSE:SN.) announces an Equity Buyback for $300 million worth of its shares.

Smith+Nephew Launches Real Intelligence and CORI Surgical System and Next Generation Handheld Robotics Platform in Canada

Smith+Nephew Launches CORI Handheld Robotics

Insider recently sold UK£160k worth of stock